Lygos Stock
Biotechnology solutions
Sign up today and learn more about Lygos Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Lygos Stock
Founded in 2010, Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production.
Investors
First Round Capital
Flexport, AppNexus, Bowery Farming, Goat Group, Blue Apron, SingleStore, DoubleVerify, Clover Health, Fab, Roblox
US Department of Energy
Funding History
| April 2012 | $150K |
|---|---|
| April 2013 | $1.0M |
| December 2014 | $550K |
| December 2016 | $13.0M |
| July 2018 | $15.5M |
| September 2018 | $2.0M |
| January 2019 | $10.0M |
| March 2019 | $750K |
| June 2019 | $2.0M |
Management
Founder & Chief Executive Officer
Eric Steen
Chief Patent Counsel
Photon Rao
Press
Business Wire - Sep, 5 2019
Lygos Upgrades Technology Capabilities to Accelerate Microbial Cell Factory Development TimelinesBusiness Wire - Aug, 7 2019
Lygos Announces Bio-DEM™ Product Qualified at Metric Ton Scale for Sirrus’ Chemilian™ and Forza™ Product LinesBusiness Wire - Jun, 3 2019
Lygos Awarded $2 Million Grant to Develop Artificial Intelligence and Machine Learning Technologies to Revive U.S. BiomanufacturingAP - May, 7 2019
Lygos Appoints Photon Rao as Chief Patent CounselSynbiobeta - Apr, 12 2019
A modern-day David-and-Goliath: How Lygos CEO Eric Steen is tackling the petrochemical industryEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
